Barely Significant
← all excerpts

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.

Oncologist · 2024 · PMC11224977 · PMID 38530254

Europe PMCDOI
1
hedged sentence
0.0546
closest p · 1.1× alpha
0.0546
boldest claim

The sentences

showed a trendP = .0546so close (0.05 < p ≤ 0.1)
In the multivariate analysis, concurrent RT emerged as the only independent factor (adjusted HR = 0.180, 95% CI: 0.051-0.632; P = .0075), while prior locoregional therapy showed a trend toward longer OS (adjusted HR = 0.351 95% CI: 0.121-1.021; P = .0546; Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.